Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
Open Access
- 1 January 2008
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 12 (1), R17
- https://doi.org/10.1186/cc6791
Abstract
In severely neutropenic septic acute respiratory distress syndrome (ARDS) patients, macrophages and monocytes are the last potentially remaining innate immune cells. We have previously shown, however, a deactivation of the alveolar macrophage in neutropenic septic ARDS patients. In the present study, we tried to characterize in vitro monocyte baseline cytokine production and responsiveness to lipopolysaccharide exposure. Twenty-two consecutive patients with cancer were prospectively enrolled into a prospective observational study in an intensive care unit. All patients developed septic ARDS and were divided into two groups: neutropenic patients (n = 12) and non-neutropenic patients (n = 10). All of the neutropenic patients received granulocyte colony-stimulating factor whereas no patient in the non-neutropenic group received granulocyte colony-stimulating factor. We compared monocytes from neutropenic patients with septic ARDS with monocytes from non-neutropenic patients and healthy control individuals (n = 10). Peripheral blood monocytes were cultured, and cytokine levels (TNFalpha, IL-1beta, IL-6, IL-10, and IL-1 receptor antagonist) were assayed with and without lipopolysaccharide stimulation. TNFalpha, IL-6, IL-10 and IL-1 receptor antagonist levels in unstimulated monocytes were lower in neutropenic patients compared with non-neutropenic patients. Values obtained in the healthy individuals were low as expected, comparable with neutropenic patients. In lipopolysaccharide-stimulated monocytes, both inflammatory and anti-inflammatory cytokine production were significantly lower in neutropenic patients compared with non-neutropenic patients and control individuals. Consistent with previous results concerning alveolar macrophage deactivation, we observed a systemic deactivation of monocytes in septic neutropenic ARDS. This deactivation participates in the overall immunodeficiency and could be linked to sepsis, chemotherapy and/or the use of granulocyte colony-stimulating factor.Keywords
This publication has 19 references indexed in Scilit:
- Monocyte Human Leukocyte Antigen–DR Transcriptional Downregulation by Cortisol during Septic ShockAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Deactivation of Alveolar Macrophages in Septic Neutropenic ARDS*Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003
- Inflammatory response to infectious pulmonary injuryEuropean Respiratory Journal, 2003
- Monocyte Deactivation in Severe Human Sepsis or Following Cardiopulmonary BypassShock, 2002
- Role of Matrix Metalloproteinases in Models of Macrophage-Dependent Acute Lung InjuryAmerican Journal of Respiratory Cell and Molecular Biology, 1999
- Biological markers of acute lung injury: prognostic and pathogenetic significance.American Journal of Respiratory and Critical Care Medicine, 1997
- Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome.American Journal of Respiratory and Critical Care Medicine, 1997
- Pulmonary macrophages.1994
- The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.American Journal of Respiratory and Critical Care Medicine, 1994
- American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.1992